Nkarta, Inc. (NKTX) Stock Score, Valuation & Financial Research

Nkarta, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for NKTX

Nkarta, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.18. These figures are a research snapshot, not a buy or sell recommendation.

What Nkarta, Inc. does

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Nkarta is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of engineered natural killer (NK) cell therapies. As a clinical-stage entity, the company does not currently generate product revenue and relies on capital raises and interest income to fund its research and development activities for its proprietary cell therapy platform.

Products and services

  • The company is developing engineered natural killer (NK) cell therapies, including its lead product candidate NKX019, which is being evaluated in clinical trials for the treatment of autoimmune diseases.

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Proprietary CAR-NK cell therapy platform Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

NKTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.18
Market capitalization:
155.61M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -117.32M
Free cash flow:
USD -89.91M
Cash:
USD 24.96M
Total debt:
USD 73.54M
EPS:
USD -1.57

What stands out

  • Free cash flow is USD -89.91M, negative for the stored period.
  • The balance sheet shows USD 24.96M of cash versus USD 73.54M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 48.58M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for NKTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can NKTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is NKTX's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for NKTX to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of NKTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research NKTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.